Loading stock data…
SGMT
$7.61-0.42 (-5.23%)
Market ClosedLast close May 1
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sagimet Biosciences Inc. in the Healthcare sector is trading at $7.61. The stock is currently 33% below its 52-week high of $11.41, remaining 12.1% above its 200-day moving average. Technical signals show neutral RSI of 67 and bullish MACD crossover, explaining why SGMT maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 67) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.61
Potential Upside
5%
Whystock Fair Value$7.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$26.10+243.0%
Range$8.00 – $35.00
Fundamentals
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$204.63M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-45.82%
Volume
Today's trading volume
1.33M
Recent News
Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise
Sagimet Biosciences (NASDAQ:SGMT) said it is sharpening its strategic focus on developing differentiated therapies for patients with moderate to severe acne, with plans to advance its lead fatty acid synthase (FASN) inhibitor, denifanstat, into a U.S. phase III registrational study in the second hal
Why Sagimet Biosciences Stock Is Soaring Today
The biopharma company confirmed it's still aiming at the United States' acne-treatment market.
Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans
Sagimet Biosciences Inc. (NASDAQ:SGMT) surged 30% on Monday after unveiling plans to launch a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.
Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results
Sagimet Biosciences Inc. (NASDAQ:SGMT) earns a place on our list of the top 10 stocks under $5 that could triple. As of March 19, 2026, 91% of analysts remain bullish on Sagimet Biosciences Inc. (NASDAQ:SGMT). The stock boasts a consensus price target of $27.50, indicating an upside of 437.27%. On March 11, 2026, in its […]
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.
Sagimet Biosciences (NASDAQ:SGMT) used an investor discussion at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference to outline its strategy around fatty acid synthase (FASN) inhibition, with development efforts centered on metabolic dysfunction-associated steatohepatitis (MASH), acne, and